The US HHS has launched a $500m initiative to accelerate the development of universal vaccines targeting viruses with ...

4D Molecular Therapeutics (4DMT) has received regenerative medicine advanced therapy (RMAT) designation from the US Food and ...

Whilst 2025 outlooks include cost impact from existing tariffs, companies have not adjusted their guidance for future ...

The SNIPRx-surf platform is designed to detect cell surface targets in tumours or cancer models, utilising gene expression, ...

The UK MHRA has granted marketing authorisation to Bavarian Nordic's Vimkunya vaccine for preventing the chikungunya virus.

As scientists explore treating genetic disorders before birth, the promise of foetal gene therapy is growing—but there are ...

The London Cancer Hub has been identified as a key district for ‘frontier innovation’ by London Mayor Sadiq Khan.

Companies are developing myostatin inhibitors for GLP-1RA-related muscle loss, but some experts question their necessity.

Dimerix and Amicus Therapeutics have signed an agreement for the US commercialisation of the former’s Phase III drug ...

The FDA has granted approval for AbbVie’s 15mg Rinvoq (upadacitinib) to treat adults with giant cell arteritis (GCA).

GSK said it remains confident it can absorb the financial impact of potential US tariffs as it posted a 4% rise in Q1 2025 ...

Biogen’s CEO Chris Vibacher said ‘a new Biogen’ is emerging following the end of its multiple sclerosis treatments heyday.